BAKER BROS. ADVISORS LP Q3 2022 Filing
Filed November 14, 2022
Portfolio Value
$15.3B
Holdings
115
Report Date
Q3 2022
Filing Type
13F-HR
All Holdings (115 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | AGLEUSDAeglea BioTherapeutics, Inc. | 3,410,106 | $1.8B | 11.75% | |
| 102 | —TCR2 Therapeutics Inc. | 753,064 | $1.4B | 8.88% | |
| 103 | ATYRaTyr Pharma, Inc. | 201,361 | $604.0M | 3.96% | |
| 104 | TARAProtara Therapeutics, Inc. | 199,671 | $591.0M | 3.87% | |
| 105 | KZRKezar Life Sciences, Inc. | 61,946 | $533.0M | 3.49% | |
| 106 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $493.0M | 3.23% | |
| 107 | CABACabaletta Bio, Inc. | 662,063 | $430.0M | 2.82% | |
| 108 | IM8NInsmed Incorporated | 19,950 | $430.0M | 2.82% | |
| 109 | FHTXFoghorn Therapeutics Inc. | 45,027 | $386.0M | 2.53% | |
| 110 | —Genetron Holdings Limited | 455,306 | $356.0M | 2.33% | |
| 111 | —Vincerx Pharma, Inc. | 241,379 | $333.0M | 2.18% | |
| 112 | SERASera Prognostics, Inc. | 201,562 | $322.0M | 2.11% | |
| 113 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $299.0M | 1.96% | |
| 114 | SRZNWSurrozen, Inc. | 833,333 | $154.0M | 1.01% | |
| 115 | —LogicBio Therapeutics, Inc. | 139,105 | $38.0M | 0.25% |
PreviousPage 2 of 2